Eloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Watertown, MA, US. The stock last traded at $17.65, down 7.98% on the session, giving a market capitalisation of $60.7M. On trailing twelve-month figures it carries a trailing P/E of -20.06, a net margin of 0.0%. Its beta of -9.95 implies it has historically moved less than the broad market.
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Eloxx Pharmaceuticals, Inc. is most often compared with the following Healthcare names: